Home > Insider Trading > Filing (0001209191-14-023241)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1517022	Akebia Therapeutics Inc.	AKBA	Pharmaceutical Preparations (2834)	208756903

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1388325	A/S Novo	Tuborg Havnevej 19 Hellerup G7 2900		No	No	Yes	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-03-25	1,333,797	$0.00	1,333,797	No	4	C	Direct
Common Stock	Acquisiton	2014-03-25	182,590	$17.00	1,516,387	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	SERIES C PREFERRED STOCK	Disposition	2014-03-25	714,285	$0.00	1,333,797	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

Series C Preferred Stock (the "Preferred Stock") had no expiration date and was convertible at any time, at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock converted into shares of the Issuer's Common Stock based on a conversion ratio equal to the Series C Accrued Value (the original issuance price of $14.00 plus accrued but unpaid cash dividends) divided by the Applicable Conversion Price of $14.00, adjusted for the 1.75 stock split, as provided in the Issuer's Eighth Amended and Restated Certificate of Incorporation.